Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 13, 2021
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
[ Wed, Jan 13th 2021
] - WOPRAI
Tue, January 12, 2021
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
[ Tue, Jan 12th 2021
] - WOPRAI
Andrew Berens Maintained (BPMC) at Buy with Increased Target to $127 on, Jan 12th, 2021
Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $121 to $127 on, Jan 12th, 2021.
Andrew has made no other calls on BPMC in the last 4 months.
There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Konstantinos Aprilakis of "Stifel" Initiated at Hold and Held Target at $110 on, Thursday, December 3rd, 2020
- Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $96 on, Monday, November 2nd, 2020
- David Lebovitz of "Morgan Stanley" Downgraded from Buy to Hold on, Friday, October 30th, 2020
These are the ratings of the 2 analyists that currently disagree with Andrew
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $120 on, Thursday, October 29th, 2020
- Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $122 on, Friday, October 16th, 2020
